| human | Q5 |
| P496 | ORCID iD | 0000-0002-8327-3439 |
| P69 | educated at | Yonsei University College of Medicine | Q45134621 |
| P108 | employer | Yonsei University College of Medicine | Q45134621 |
| P106 | occupation | researcher | Q1650915 |
| Q57213019 | A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure |
| Q33872970 | Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. |
| Q90873492 | An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate |
| Q90840683 | An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia |
| Q90332014 | Awareness and Access to Therapy in Hepatitis C Virus Infected Patients, Key Barriers to Eliminate the Virus? |
| Q42332098 | Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? |
| Q57469986 | Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study |
| Q40580971 | Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. |
| Q41808225 | Current status of and strategies for hepatitis C control in South Korea |
| Q64115269 | Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis |
| Q91725808 | External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy |
| Q95840086 | Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase |
| Q89745437 | Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy |
| Q92976450 | Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study |
| Q99204246 | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
| Q94477296 | Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B |
| Q93085575 | Postoperative Recurrence of Hepatocellular Carcinoma: The Importance of Distinguishing between Intrahepatic Metastasis and Multicentric Occurrence-Response |
| Q53081188 | Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. |
| Q104681933 | Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma |
| Q90878297 | Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study |
| Q90067935 | Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus |
| Q89153286 | Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B |
| Q48368436 | Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update? |
| Q125345589 | Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis |
| Q89681374 | The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization |
| Q91253983 | [New Systemic Therapies for Advanced Hepatocellular Carcinoma] |
Search more.